Viela Bio to Report Fourth Quarter and Full Year 2020 Operating and Financial Results on March 1, 2021
GAITHERSBURG, Md., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Viela Bio (Nasdaq:VIE), a biotechnology company dedicated to the discovery, development and commercialization of novel treatments for patients suffering from autoimmune and severe inflammatory diseases, today announced it will report its fourth quarter and full year 2020 operating and financial results after the U.S. financial markets close on Monday, March 1, 2021.
In light of the agreement and plan of merger by and among Viela Bio, Horizon Therapeutics, Inc., Teiripic Merger Sub, Inc., and Horizon Therapeutics plc, announced on February 1, 2021, Viela will not be hosting a conference call for its fourth quarter 2020 results. Earnings materials will be made available publicly on the Investor Relations page of Viela’s website at www.vielabio.com.
About Viela Bio
Viela Bio, headquartered in Gaithersburg, Maryland, is a biotechnology company dedicated to the discovery, development and commercialization of novel treatments for patients suffering from autoimmune and severe inflammatory diseases. For more information, please visit www.vielabio.com.
Source: Viela Bio